Abstract Background: Thrombomodulin (TM) is a surface glycoprotein and expressed in many cancers. The aim of the present study was to detect the expression levels of TM in plasma and urine of bladder cancer patients and to compare these levels to the clinicopathological data of the patients as well as the ploidy status of their exfoliated urinary cells. We studied the levels of TM in plasma and urine samples of 57 bladder cancer patients and 10 controls using the (ELISA) assay and compared the results to the ploidy status of the cells taken from the patents urine samples as well as their clinicopathological profile.
Introduction
Thrombomodulin is a thrombin receptor expressed on the endothelium which acts as a cofactor for thrombin-catalyzed activation of protein C [6, 8] . The presence of thrombomodulin was demonstrated throughout the vascular and lymphatic endothelium, and syncytio-trophoblast [16] . Circulating TM reflects proteolysis of endothelial membrane TM that is produced either as a result of the turnover of TM or as a result of endothelial damage in areas of endothelial injury or inflammation [4, 6, 9] . Recent studies revealed that thrombomodulin is expressed in varying amounts by different additional cell types including platelets [21] and monocytes [22] . Since these cells come in contact with the blood, thrombomodulin on these cells may regulate blood coagulation on the cell surface. Thrombomodulin is also reported to be expressed in the squamous epithelium and carcinoma, suggesting that thrombomodulin may play some role in cell-cell interaction [8] . Thrombomodulin has been reported to be present in plasma P-TM as well as in urine U-TM [21] , in various molecular forms and with different electrophoretic motilities [22] . P-TM is probably released from endothelial cell membranes by proteolytic cleavage and its level is increased in disease possibly involving endothelial cell injury [8] . The level of circulating P-TM may be useful as a critical marker of vascular endothelial damage, disease recurrence and angiogenesis in certain malignancies [9] . The electrophoretic mobility of U-TM was found to be similar to that of P-TM and lack 29 amino acid of the c-terminal sequence of cellular thrombomodulin [12] . According to studies conducted in the National Cancer Institute of Egypt: bladder cancer continues to be the most frequent cancer today in Egyptian men and 32% of all malignant tumor registered in the NCI. It tends to occur at unpredictive course and limited tendency to lymphatic and blood stream spread [1, 2, 3] .
Tumor metastasis is a complex series of multi-step process. One process is the detachment of cancer cells into blood circulation and another is the adhesion of such cells to endothelial cells [13] . Several investigators have previously reported on the relationship between coagulation activity and tumor metastasis. Thrombomodulin was demonstrated recently to be expressed on the urinary bladder epithelium. Thrombomodulin is known to inhibit fibrin formation and platelet activation that stimulates tumor cell bindings to endothelial cells. Therefore it is critical to the pathogenesis of tumor growth and metastasis formation [15, 18] . In this study we evaluated the expression levels of both urinary and plasma soluble thrombomodulin in bladder cancer patients and its relation to the clinico-pathological data as well as the DNA ploidy status to these patients.
Patients and methods
This study included a total of 58 cases with diagnosed bladder cancer attending to the National Cancer Institute -Egypt and 10 aged matched normal controls.
Inclusion criteria: only new cases with clinically diagnosed bladder cancer were involved in the study. Selection of the patients have been done depending on the results of endoscopy.
After approval of the ethical committee of the National Cancer Institute, Cairo University, samples were collected from the patients before being subjected to any type of therapy. For those who had radical cyctectomy as a primary treatment modality, diagnosis of bladder cancer was confirmed by histo-pathological examination of the removed tumor tissues. Thrombomodulin in both urine and plasma levels were determined using the enzyme linked immunosorbent assay (ELI-SA). The ploidy status analysis was done on exfoliated cells separated from 39 urinary samples using the flow cytometry.
Methods
Blood samples were collected from patients on 3.2% trisodium citrate solution as an anti coagulant. The samples were centrifuged at 3000 rpm for 20 min. Plasma was separated and stored in À80°C. Fifty milli liters of voided morning urine samples were collected from patients into 50 ml sterile Falcon tubes before therapy and transferred to the laboratory. Urine samples were centrifuged at 1200 rpm for 20 min. The supernatant was separated in a separate sterile tube and kept frozen at À80°C, while the cell pellets of the urine samples were washed with PBS (pH 7.2), centrifuged again. The pellets were re suspended in PBS and the cells were counted where the total volume was diluted to 1 million cells/ml and transferred to the flow cytometry laboratory. The DNA ploidy status of the cells was detected using FACS Calibur BECTON DICKNSON flow cytometry model. The FACS caliber is adjusted to withdraw 10,000 cells from each sample. Samples were run and proper gating of desired population was done to exclude any debris. The thrombomodulin in plasma and urinary samples was measured by using a two-site enzyme-linked immunosorbent assay (ELISA) purchased from Diagnostica Stago [21] .
Results
The DNA ploidy status was studied on a total of 39 samples. Twenty-five cases (64.1%) were diploid and 14 (35.9%) cases were aneuploid (Table 1) . P-TM in bladder cancer patients group showed statistically higher significant mean value as compared to the mean value of P-TM in normal healthy control group (59.2 vs. 30.3) p = 0.006 ** ( Table 2 ). P-TM in bladder cancer patients were correlated to the clinico-pathological findings: (Table 3 ). There was no statistically significant correlation between the level of TM-P and any of the clinic-pathological parameters including age, sex, bilharzial infection, histopathological grade, clinical stage lymph node involvement. By studying the correlation between TM-P and tumor size we found that there was a positive correlation between the level of P-TM and the tumor size but the correlation did not reach the level of significance (P = 0.063). However, P-TM was significantly higher in SCC patient as compare to TCC patients (76 ± 46.9 vs. 48 ± 22.2) P = 0.019.
By studying the DNA Ploidy status in exfoliated urinary cells of the 39 bladder cancer cases, we found that P-TM showed higher mean values in aneuploid as compared to diploid however the difference failed to reach the level of significant values p = 0.180 (Table 4) .
We used the ROCK curve to study the sensitivity and specificity of TM-P (Fig. 1) . Sensitivity was 76% while the specificity was 80%.
U-TM in cancer bladder patient showed statistically significant reduction of the mean value as compared to the normal control U-TM (360.9 vs. 868.3) p = 0.00001 ** (Table 2 ). We did not find any significant correlation between the levels of U-TM in bladder cancer patients and any of the clinicopathological criteria including age, sex, tumor type, tumor grade, clinical stage, lymph node metastasis, bilharzial infection and tumor size: (Table 3 ). There was no significant correlation between the results of the ploidy status and the levels of TM-Whereas the levels of U-TM were the same in both groups (P = 0.9) ( Table 4 ). The ROCK curve analysis showed that the sensitivity and specificity of U-TM were 90% and 86%, respectively (Fig. 2) .
Discussion
We reported the presence of soluble TM in plasma and urine of normal subjects as well as in bladder cancer. Our findings agree with other investigators who noted that their physiological significance were obscure [16] . In our study the mean level of U-TM was 28 folds higher than P-TM in the normal control group. The difference in the level of TM in plasma and urine in normal subjects could be attributed to their different origin [11, 12] . In the present study the soluble TM in plasma tends to significantly increase in bladder cancer as compared to healthy normal control. It is known that cancer patients may have increased amounts of proteolytic enzymes in plasma, which could explain increased levels of circulating TM fragments [16] . P-TM levels higher than normal were noticed in all terminal phase cancer cases [14] . This increase may be due to increased endothelial cell damage upon chemical damage and by activated polymorph nuclear white cells. Additional mechanisms for endothelial injury in cancer are the marked interaction of cytokine-activation lymphocyte with cytokineactivation endothelial cells causing endothelial cell damage leading to increase TM levels and T-helper 2 cell pattern supporting a humoral autoimmune process. However, this does not exclude the possibility that some tumor cells may secrete TM in vivo [5, 13] . It is probably influenced by several or all of these mechanisms.
According to this study soluble TM in plasma was statistically higher in SCC as compared to TCC. In conflict with our results, previous trials using immunohistochemical staining of TM in different cancer types to distinguish TCC from SCC proved that it was of no practical value. On 2011 Tsuta K and colleagues examined a panel of 10 antibodies including TM to distinguish SCC from AC of the lung. Although the sensitivity and specificity of TM was 79.3% and 79.9%, respectively, he found other marker more sensitive and more specific than TM. He concluded that CK5/6 is the best marker for differentiating SCC and AC and the combination of CK5/6 and TIF-1 is the most recommended combination of immunohistochemical markers. [23] . However we found a statistically non significant difference between the level of P-TM and tumor grade, clinical stage, lymph node status as well as DNA ploidy status. On the other hand there was a borderline significant positive correlation between the level of P-TM and tumor size (P = 0.063).
It was suggested that the increased cleavage of endothelial TM is unfavorable for cancer patients and contribute to the imbalance in homeostasis observed in these patients; this could explain the tendency to higher P-TM in our study in bladder cancer with indications of aggressiveness [17, 18] . P-TM level showed great variation between different cancer types: as in lung cancer, pancreases, colorectal, gastrointestinal but failed to reach statistical significance except in progression of malignant disease and terminal metastasis [10, 14, 16] . P-TM in cancer lung was extensively studied: on 1999 Yelmaz et al. reported that the concentration of soluble TM in plasma of lung cancer patients was of non-significant value as compared to control. Zekanowaska on 2001 noted that no difference between patients at different stages of lung cancer and considered TM as an unacceptable tumor marker in lung cancer. [13, 16] .
On the contrary, soluble TM tends to significantly decrease in urine of bladder cancer as compared to healthy normal controls. Investigators noted that the epithelium of the urinary bladder normally expresses thrombomodulin at both mRNA and protein levels [8] . Other investigators ascertained Table 4 The correlation between TM-levels and the DNA ploidy status of the exfoliated urinary cells. Figure 1 Shows the sensitivity and specificity of P-TM. Figure 2 Shows the sensitivity and specificity of U-TM expression and localization of TM in the human urinary bladder by immunohistochemical staining which is localized in the membranes of the transitional epithelium and the cytoplasmic region of umbrella cells. Based on these results it was concluded that TM in urine might be partially derived from urinary bladder [7] . However some investigators assumed that U-TM is probably derived from plasma [20] . Recently, it was demonstrated that TM is expressed on the surface of several tumor cells using immunohistochemistry and its degree of expression negatively correlated with malignancy in cancer [18] . This was confirmed in our study which shows a significant reduction in the level of soluble U-TM in bladder cancer as compared to normal controls. They explained the decrease of the TM associated with cancer as it probably involves the presence of a factor secreted by the tumor cells, responsible for a decrease in TM synthesis in endothelial cells, as is in vitro: inflammatory cytokines (IL-1, TNF alpha) have been shown to reduce TM synthesis in cultured endothelial cells [19] . The decrease in TM level may also be related to the methylation of the TM promoter region, Nocchi and colleagues on 2011 found that the methylation of TM promoter is responsible for silencing of TM expression in malignant mesothelioma tissue. [24] . Hossaka et al. on 2000 reported that soluble TM isolated from human urine affects the invasion and metastasis, while Kaido et al. 1999 used U-TM to ameliorate fibrin deposition, hepato-cellular necrosis and improve the survival rate of control rats [10, 11] .
By analyzing the sensitivity and specificity of both urinary and plasma TM, we found that U-TM was more sensitive and more specific than P-TM. This result may suggest a possible urinary bladder cancer cell origin for U-TM and also suggest a possible role for U-TM as a predictive marker in bladder cancer.
Conclusion
The results of the present study may show the following: 1 -U-TM is significantly down regulated in bladder cancer as compared to normal control group. 2 -P-TM is significantly up regulated in bladder cancer in relation to the control group. 3 -U-TM has superior sensitivity and specificity over P-TM. 4 -A possible role of U-TM in the prediction of urinary bladder cancer 5 -Other Studies are clearly needed to test the prognostic role of U-TM in bladder cancer.
